The action charges Akero with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a ...
If you suffered losses exceeding $75,000 investing in Akero stock or options between September 13, 2022 and October 9, 2023 ...
Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with ...
LOS ANGELES, CA / ACCESSWIRE / June 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...
June 3, 2024) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ: ...
BofA Securities raised the price target for the Akero Therapeutics Inc (NASDAQ:AKRO) stock to “a Neutral”. The rating was released on April 22, 2024, according to finviz. The research report from UBS ...
SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious ...
Foti, Jr., remind investors that they have until June 25, 2024 to file lead plaintiff applications in a securities class action lawsuit against Akero Therapeutics, Inc. (NasdaqGS: AKRO), if they ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
1d
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gilead Sciences (GILD – Research Report) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback